Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HS-20197
- Development stage
- Phase 1
- Lead developer
- Hansoh Pharmaceutical Group
- Administration
- Intravenous
01
Overview
HS-20197 is an investigational Class 1 therapeutic biological product being developed by Hansoh Pharma and its subsidiary Changzhou Hengbang for the treatment of advanced solid tumors. The specific target and mechanism of action of HS-20197 have not yet been publicly disclosed. It is currently being evaluated in an ongoing Phase 1 clinical trial in China to assess its safety, tolerability, pharmacokinetics, and preliminary antitumor activity in patients with advanced solid tumors.
- Other names
- 注射用HS-20197
Beyond the preview
Go deeper on HS-20197.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HS-20197.